Skip to main content

Critical gaps in Health Information

Giving people incentive to digitise medical data can help fill critical gaps in health information


It is time for data governance in India to prioritise empowering citizens’ to use their data as their property, held or sold at will, rather than treating it as a sacred and inalienable element of their identity

India’s population of 1.4 billion exceeds that of the entire bloc of 38 OECD countries. Given the rapid pace of expansion of technology in India, it is not unreasonable to believe that the value of data generated by Indian citizens in their daily lives may already, or very soon, match the value of data generated by citizens of these countries, when adjusted for purchasing power parity. Enabling this outcome should be a key priority for the architects of India’s data governance policies.

While there has been frenetic activity in the space of digital governance in the country, we believe that there is a fundamental misunderstanding in the current policy mix. Decision-makers are finding it difficult to differentiate between data as a form of identity and data as a form of property. This failure to differentiate is holding back key areas of value creation and knowledge discovery.

Nowhere is this impact more keenly felt than in the utilisation of healthcare data in India, or the lack thereof. While large private hospitals have bespoke digital systems and government hospitals have been dragged willy-nilly into maintaining some rudimentary digital capabilities by the good offices of the National Health Mission, a large fraction of Indian citizens’ healthcare consultations occur in small private clinics with no real incentive to digitise, thereby preventing patients and downstream physicians from acquiring an interoperable digital trail of medical records.

This lack of digital records also makes it difficult for health insurers to compete on pricing, for clinical researchers to run large-sample analyses to discover new treatments, and for AI researchers to train diagnostic or decision support models on large datasets.

The fact that the healthcare data ecosystem in India remains frozen is not for want of governance efforts to facilitate data access. The National Health Authority has, in the recent past, outlined a framework for health data exchange based on two basic principles. One, that the citizen was the owner of their health records. And two, that they should be able to access them in any health facility, which subsequently has been operationalised nationwide as the Ayushman Bharat Digital Mission (ABDM). Its building blocks include registries for doctors, drugs and health facilities, middleware for information processing functions, and a consent management system that enables citizens to share their electronic health records with any registered health provider.

However, ABDM’s implementation faces a basic challenge: Clinical data is generated via an interaction between the patient and doctor, and neither is, in the moment of that interaction, interested in the future value of the data created in that encounter. For clinical data to become available, it must first become valuable. Once citizens find value in their personal health records, the innovation ecosystem surrounding health IT systems will, over time, create the best possible interfaces for doctors and health data fiduciaries to unlock that value for them.

If patients are allowed to make their health records available to commercial vendors, they will patronise healthcare establishments that are compliant with ABDM’s data interoperability and storage requirements and that put in the work to record and store data correctly. Patients interested in maintaining complete medical records will naturally simplify consultative processes for doctors, since case histories will become more accessible. An array of data intermediaries will spring up to create health information exchanges.

What is it, then , that prevents the adoption of free markets for data sharing in India? In our view, it is a mistaken prejudice, borrowed unthinkingly from the West, privileging a nebulous sense of privacy at the expense of concrete economic rights in the framing of data governance policies. In the US, the Health Insurance Portability and Accountability Act (HIPAA) places restrictions on how medical records are to be stored. The HIPAA grants patients the right to access their medical records from any provider, but not the right to make their health records available to a third party. The Act permits hospitals and other third parties to buy and sell patient records, once they have been anonymised. As a result, hospitals, insurance companies and other stakeholders monetise de-identified patient data to the tune of billions of dollars in economic value, of which the patients themselves see no share.

On the other side of the Atlantic, UK data governance principles make it clear that it is healthcare institutions, not patients, that own patients’ medical records. However, in practice, nearly 90 per cent of health records in the UK are created by the National Health Service (NHS) through one of its organs, and thus are owned by the NHS, to use as determined by internal policies.

Neither the corporatist model of data governance embedded in the HIPAA, nor the statist model of data governance embedded in the data governance principles of the UK — and the EU — healthcare systems are a good fit for the Indian healthcare system, which is highly privatised and highly decentralised. We instead advocate citizen-centric data governance.

Of course, no free market can exist without regulations and safeguards. Extremely effective technical tools for the removal of personally identifiable information exist and can be offered as digital public goods to citizens so that they can preserve their privacy while participating in a free market for information. Similarly, effective digital forensics tools exist to remove asymmetries in the information market. It is time for data governance in India to prioritise empowering citizens to use their data as their property, held or sold at will, rather than treating it as a sacred and inalienable element of their identity.

wellness, nutrition, fitness, mental health, exercise, healthy diet, sleep hygiene, stress management, hydration, immunity, preventive care, chronic disease, weight loss, mindfulness, self-care, healthcare access, medical research, physical activity, balanced lifestyle, healthy habits

#Wellness, #Nutrition, #FitnessGoals, #MentalHealthMatters, #ExerciseDaily, #HealthyEating, #BetterSleep, #StressRelief, #StayHydrated, #BoostImmunity, #PreventiveCare, #ChronicIllness, #WeightLossJourney, #MindfulnessPractice, #SelfCareSunday, #HealthEquity, #MedicalResearch, #ActiveLifestyle, #HealthyChoices, #LiveWell


International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...